Supported by Science

Pain & Inflammation:
  • The CB2 receptor and its role as a regulator of inflammation (Cell Mol Life Sci. 2016; 73(23): 4449-70.)
  • Targeting CB2 receptors and the endocannabinoid system for the treatment of pain (Brain Res Rev. 2009 Apr; 60(1): 255-266.)
  • Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain (Br J Pharmacol. 2008 Jan; 153(2): 319–334.)
  • The central cannabinoid receptor type-2 (CB2) and chronic pain. (Int J Neurosci. 2017 Sep;127(9):812-823.)
Anxiety
  • Anxious behavior induces elevated hippocampal CB2 expression. (Neuroscience. 2017 Jun 3;352:273-284.)
  • Regulatory role of the CB2 receptor in stress-induced neuroinflammation. (Br J Pharmacol. 2014 Jun;171(11):2814-26.)
Degenerative neurological conditions:
  • Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with a focus on neurodegenerative disorders (Front Neurosci. 2016; 10: 406.)
  • Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential (Neural Regen Res. 2016 Sep; 11(9): 1409–1410.)
  • CB2 receptor: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)
  • Cannabinoid CB2 receptors in human brain inflammation (Br J Pharmacol. 2008 Jan; 153(2): 277–285.)
Multiple Sclerosis:
  • CB2 receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies (Br J Pharmacol. 2008 Jan; 153(2): 216–225.)
  • Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis. (J Neuroimmunol. 2017 Feb 15;303:66-74.)
Alzheimer's Disease
  • CB2 cannabinoid receptor as potential target against Alzheimer’s Disease (Front Neurosci. 2016; 10: 243.)
Parkinson's Disease
  • Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s Disease (Front Neurosci. 2016; 10: 321.)
  • CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease (Exp Mol Med. 2016 Jan; 48(1): e205.)
Osteoarthritis:
  • Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint (PLoS One. 2013; 8(11): e80440.)
  • Expression of cannabinoid receptors in human osteoarthritic cartilage: Implications for future therapies (Cannabis Cannabinoid Res. 2016 Jan 1;1(1):3-15)
Rheumatoid arthritis:
  • CB2 as a potential therapeutic target in rheumatoid arthritis (Musculoskeletal Disorders. 2014; 15: 275.)
  • CB2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis (Rheumatology. 2014; 53(5): 802-809.)
  • Role of CB2 in mediating inflammation in rheumatoid arthritis synovial fibroblasts. (Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1026-1035.)
Immune system modulation:
  • CB2: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)
  • Emerging role of the CB2 cannabinoid receptor in immune regulation and therapeutic prospects (Expert Rev Mol Med. 2009 Jan 20; 11: e3.)
Cardiovascular:
  • CB2 drives neurogenesis and improves functional outcome after stroke (Stroke. 2017 Jan;(48)1:204-212.)
  • Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists (J Cardiovasc Pharmacol Ther. 2016 May;21(3):262-72.)
  • CB2 in atherosclerosis and acute cardiovascular diseases (Curr Med Chem. 2014;(21)35:4046-58.)
  • CB2 receptor stimulation attenuates the initiation and progression of atherosclerosis. (Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8.)
  • Time-Dependent Protection of CB2 Receptor Agonist in Stroke. (PLoS One. 2015 Jul 17;10(7):e0132487.)
  • Selective Modulator of CB2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia. (Curr Neurovasc Res. 2016;13(4):289-302.)
  • The Endocannabinoid System and Heart Disease: The Role of CB2. (Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34-51.)
Metabolic Disorders:
  • CB2 receptor agonist improves systemic sensitivity to insulin (Cell Physiol Biochem. 2016;40(5):1175-1185.)
  • Anti-Obesity Effect of a CB2 Receptor Agonist in Diet-Induced Obese Mice. (PLoS One. 2015 Nov 20;10(11):e0140592.)
Digestive Disorders:
  • CB2 receptor-induced relief of hypermotility in a rat model of the irritable bowel syndrome (Neurogastroenterol Motil. 2019 Jun;31(6):e13613.)
  • Cannabinoids and intestinal motility: welcome to CB2 receptors. (Br J Pharmacol. 2004 Aug;142(8):1201-2.)
Migraine:
  • Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model (J Headache Pain. 2014; 15(1): 14.)
Eye Health
  • Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. Prostaglandins Other Lipid Mediat. 2018 Nov;139:54-62.
  • CB2 receptors are upregulated with corneal injury and regulate the course of corneal wound healing. Exp Eye Res. 2019 May;182:74-84.
  • Activation of CB2 by selective agonists regulates the deposition and remodelling of the extracellular matrix. Biomed Pharmacother. 2017 Nov;95:1704-1709.
  • CB2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. Neuropharmacology. 2017 Feb;113(Pt B):627-638.
  • CB2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation. Clin Hemorheol Microcirc. 2015;61(2):237-49.
Skin Health:
  • CB2 exerts antifibrotic effects in experimental dermal fibrosis. (Arthritis Rheum. 2009 Apr;60(4):1129-36.)
Respiratory Health:
  • CB2 agonist prevents nicotine induced lung fibrosis. (Exp Lung Res. 2018 Sep;44(7):344-351.)